Skip to main content

Table 3 Multivariate regression analyses of motor complications correlates among 737 L-dopa/DCI users

From: Chinese culture permeation in the treatment of Parkinson disease: a cross-sectional study in four regions of China

Variable

Dyskinesias

P Value

Motor fluctuations

P Value

 

Yes / no

OR (95% CI)

 

Yes / no

OR (95% CI)

 

Age at onset (yr)

≥59

30 / 420

Reference

0.15

68 / 382

Reference

0.13

 

<45

11 / 49

2.32 (1.00 – 5.41)

 

14 / 46

1.20 (0.57 – 2.53)

 
 

45-58

22 / 205

1.31 (0.70 – 2.46)

 

55 / 172

1.63 (1·02 – 2·61)

 

PD duration (yr)

<5

15 / 399

Reference

0.36

30 / 384

Reference

0.02

 

5-9

28 / 188

1.88 (0.79 – 4.51)

 

64 / 152

2.52 (1.31 – 4.85)

 
 

≥10

20 / 87

1.82 (0.59 – 5.59)

 

43 / 64

2.46 (1.05 – 5.76)

 

Hoehn -Yahr stage

<3

38 / 540

Reference

0.03

76 / 502

reference

<0.001

 

≥3

35 / 134

2.03 (1.08 – 3.82)

 

61 / 98

2.58 (1.62 – 4.11)

 

LD dose, mg/d

<400

16 / 370

Reference

0.02

39 / 347

Reference

0.002

 

400-599

21 / 149

2.48 (1.20 – 5.13)

 

37 / 133

1.69 (0.99 – 2.91)

 
 

≥600

26 / 155

2.44 (1.20 – 4.98)

 

61 / 120

2.48 (1.49 – 4.14)

 

LD/DCI duration (yr)

<2

14 / 294

Reference

0.44

23 / 285

Reference

0.07

 

2-4

15 / 215

1.04 (0.47 – 2.34)

 

36 / 194

1.58 (0.86 – 2.87)

 
 

≥5

34 / 165

1.73 (0.66 – 4.51)

 

78 / 121

2.42 (1.14 – 5.12)

 

Months to initiate

≤12

27 / 339

Reference

0.87

66 / 300

Reference

0.66

LD/DCI use

>12

36 / 439

0.95 (0.49 – 1.83)

 

71 / 300

0.89 (0.54 – 1.48)

 

Initial treatment

non LD/DCI

22 / 119

Reference

0.04

35 / 106

Reference

0.42

 

LD/DCI only

22 / 259

0.46 (0.22 – 0.95)

 

53 / 228

0.76 (0.42 – 1.36)

 
 

LD/DCI + others

19 / 296

0.41 (0.19 – 0.87)

 

49 / 266

0.67 (0.37 – 1.22)

 
  1. Abbreviations: LD, L-dopa; DCI, decarboxylase Inhibitor; OR, odds ratios; CI, confidence interval.
  2. Model adjusted for gender, age at onset, PD duration, Hoehn -Yahr stage, levodoap dose, LD/DCI duration, region, months to initiate LD/DCI use, and initial treatment.